Yissum - Research Development Company of the Hebrew University

New Ti(IV) metal complexes of salan ligands as anti-cancer agents

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

New Ti(IV) metal complexes of salan ligands as anti-cancer agents
Project ID : 7-2010-2497

Description of the technology

New family of cytotoxic complexes with potentially less side effects

Categories

Oncology/cancer, Drug discovery, Apoptosis

Development Stage

Established in vitro; currently undergoing in vivo and mechanistic studies

Patent Status

A provisional patent application has been filed

Market

In 2006, cytotoxics of the platinum family, which include cisplatin, carboplatin and oxaliplatin, contributed around $3.5 billion (17%) of global cytostatics sales

Highlights

  • Metal based anti-tumor therapeutics cisplatin and carboplatin are two of the most widely prescribed anticancer agents.
  • However, there is a finite number of tumors that can be treated with cisplatin and it causes extreme toxic effects such as neurotoxicity, nephrotoxicity and others.
  • Ti(IV) complexes with various cyclopentadienide or diketonato ligands demonstrate cytotoxic activity towards cisplatin-resistant and -sensitive cells with substantially reduced and mostly reversible side effects.
  • However, the currently known compounds display rapid hydrolysis in aqueous environment to give a mixture of unidentified products. The final decomposition product, titanium dioxide, is inert and often used in food and cosmetics as a whitening pigment.
  • There is a need for Ti(IV) complexes with better suited and rationally designed stabilizing ligands that demonstrate enhanced hydrolytic stability and improved anti-tumor properties.
  • Salans are well known diamine bis(phenolato) compounds which have been used as chelating ligands for a wide variety of transition metals for various applications.

Our Innovation

New family of Ti(IV) salan complexes as a new family of highly cytotoxic compounds designed to include a single highly electron-donating chelating ligand to afford octahedral TiIV complexes of relatively high hydrolytic stability, with the aim of retaining ligand binding throughout the biological activity for achieving controlled processes and allowing mechanistic evaluation.

Key Features

  • Cytotoxicity greater than that of Cp2TiCl2, (bzac)2Ti(OiPr)2 and cisplatin towards colon, ovarian, melanoma, leukaemia, breast and other cells.
  • Particularly slow hydrolysis and defined hydrolytic process; the labile isopropoxo ligands hydrolyze within weeks in 1/9 water/THF solutions and the resulting salan-bound cluster does not further hydrolyze for days.
  • A correlation is observed between the hydrolytic behavior and cytotoxicity, both features are tenable by structural modifications on the ligands.
  • Some mechanistic insights include clear participation of the ligand-bound species in activity, identification of the cellular target as chiral (presumed to be DNA), and more.

Development Milestones

Seeking funding for ongoing research and collaboration with pharmaceutical companies to establish in vivo toxicity and activity and develop products

The Opportunity

  • Opportunity to develop cure for a wide range of cancer types using a biologically-friendly metal core that causes reduced side effects
  • All the cell lines of the seven tested so far show response to these compounds

Project manager

Shoshana Keynan
VP, Head of Business Development, Healthcare

Project researchers

Edit Tshuva
HUJI, Faculty of Science
The Institute of Chemistry

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • Oncology / Cancer
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.